Intensity-modulated versus 3-dimensional conformal radiotherapy in the definitive treatment of esophageal cancer: comparison of outcomes and acute toxicity

Matthias Felix Haefner, Kristin Lang, Vivek Verma, Stefan Alexander Koerber, Lorenz Uhlmann, Juergen Debus, and Florian Sterzing

Abstract

Background: Though the vast majority of seminal trials for locally advanced esophageal cancer (EC) utilized three-dimensional conformal radiotherapy (3DCRT), the advanced and highly conformal technology known as intensity-modulated radiotherapy (IMRT) can decrease doses to critical cardiopulmonary organs. To date, there have been no studies comparing both modalities as part of definitive chemoradiation (dCRT) for EC. Herein, we investigated local control and survival and evaluated clinical factors associated with these endpoints between cohorts.

Methods: We retrospectively analyzed 93 patients (3DCRT n = 49, IMRT n = 44) who received dCRT at our institution between 2000 and 2012 with the histologic diagnosis of nonmetastatic EC, a Karnofsky performance status of ≥70, curative treatment intent, and receipt of concomitant CRT. Patients were excluded if receiving <50 Gy. Kaplan-Meier analysis was used to evaluate the endpoints of local relapse rate (LR), progression-free survival (PFS), and overall survival (OS). Cox proportional hazards modeling addressed factors associated with outcomes with univariate and multivariate approaches. Rates of acute toxicities and basic dosimetric parameters were compared between 3DCRT and IMRT patients.

Results: Mean follow-up was 34.7 months. The 3-year LR was 28.6% in the 3DCRT group and 22.7% in the IMRT group (p = 0.620). Median PFS were 13.8 and 16.6 months, respectively (p = 0.448). Median OS were 18.4 and 42.0 months, respectively (p = 0.198). On univariate analysis, only cumulative radiation dose was associated with superior LR (hazard ratio (HR) 0.736; 95% confidence interval (CI) 0.635 – 0.916, p = 0.004). Factors clearly affecting survival were not observed.

Conclusions: When comparing 3DCRT- versus IMRT-based dCRT, no survival benefits were observed. However, we found a lower local recurrence rate in the IMRT group potentially owing to dose-escalation. Prospective data are needed to verify the presented results herein.

Keywords: Esophageal cancer, Chemoradiotherapy, Toxicity, Radiation therapy, Intensity-modulated radiotherapy, Three-dimensional conformal radiotherapy
Background

Though the current standard of care for locally advanced esophageal cancer (EC) is neoadjuvant chemoradiotherapy (nCRT) followed by resection [1, 2], the latter is also associated with surgical morbidity and mortality. Two randomized trials have addressed nCRT versus definitive CRT (dCRT); despite local control (LC) benefits with surgery, no differences were discerned in distant metastasis or survival [3, 4]. Thus, dCRT is performed – and is indeed a viable recommendation – for select ECs [1, 5, 6].

However, virtually all seminal clinical trials for both nCRT and dCRT have utilized three-dimensional conformal radiotherapy (3DCRT) [2–4, 7, 8]. The advanced and highly conformal technology of intensity-modulated radiotherapy (IMRT) has heretofore been studied only in limited capacities [9–13]. It remains an attractive modality largely owing to the intimate anatomic relationship of the esophagus with both lungs and the heart. Indeed, several publications have posited a positive correlation between radiation dose to the lungs [14–18] and heart [19–22], with the risk of toxicities in these structures. Hence, the high conformality of IMRT could theoretically afford fewer toxicities to these organs-at-risk (OARs), especially in the setting of relative dose-escalation with dCRT, but supportive data are currently lacking. The aim of this study was to compare outcomes and acute toxicity of EC patients receiving definitive dCRT with either 3DCRT or IMRT.

Methods

This single-institutional study was approved by the university institutional review board and ethics committee, and patient/treatment/outcomes were retrospectively collected from an institutional database. Herein, we evaluated 93 patients (2000–2012) treated definitively for locally advanced EC. Specifically, inclusion criteria were histologically-proven esophageal squamous cell or adenocarcinoma, Karnofsky performance status (KPS) ≥70, curative treatment intent, systemic workup negative for distant metastases, and receipt of concomitant CRT. Patients were excluded if receiving <50 Gy definitively, as per prior studies [2]. The choice of radiation modality (IMRT or 3DCRT) was made at the radiation oncologist’s discretion, predominantly influenced by institutional guidelines and availability at the time of treatment planning.

All patients underwent systemic workup with referring providers prior to commencing CRT and a CT for radiation treatment planning. The gross tumor was first contoured, followed by a 4–5 cm craniocaudally from the dental arcade, 0.5-1 cm radially. The tumor border (23.7 vs. 26.4 cm from the dental arcade, \( p = 0.031 \)) and no adjustment for multiple testing is applied. Chi-squared test assessed measures of association in frequency tables, and the t-test evaluated the equality of population distributions. Survival analysis was done using Kaplan-Meier methodology. A local relapse (LR) was defined as the locally recurrent disease including a biopsy-proven or radiologically-suspicious lesion in close proximity to the initial disease. Progression-free survival (PFS) was defined as the time from last oncologic treatment to death, local recurrence or distant metastasis, whichever occurred first. Overall survival (OS) referred to the time interval between initial diagnosis to death from any cause, with censoring based on particular follow-up times. The Cox proportional hazards model was used for univariate analysis (UVA) and multivariate analysis (MVA) to assess the effect of several clinical factors on LR, PFS and OS. The Wald test was used to assess the predictive value of the covariates in the model.

Toxicities were assigned at the time of initial occurrence by the treating physician according to the Common Terminology Criteria for Adverse Events v4.0, and retrospectively reviewed for purposes of this study.

Results

Median and mean follow-up for all patients was 20.1 months and 34.7 months, respectively (range, 3 – 150.1 months). Table 1 displays clinical characteristics of the patient population. Of note, differences between groups included a more proximally localized upper tumor border (23.7 vs. 26.4 cm from the dental arcade, \( p = 0.031 \)) and a higher mean cumulative radiation dose (57.2 vs. 55.4 Gy, \( p = 0.01 \)) for the IMRT group.
Table 1 Characteristics of the patient cohort separated by radiotherapy technique

| Characteristic                        | 3DCRT (n = 49) | IMRT (n = 44) | p-value |
|---------------------------------------|----------------|---------------|---------|
| Age – years                           |                |               | 0.448   |
| Mean                                  | 64.2           | 62.9          |         |
| Median                                | 65             | 62            |         |
| Range                                 | 45-84          | 40-79         |         |
| Male Sex – no. (%)                    | 42 (85.7)      | 36 (81.8%)    | 0.610   |
| KPS – %                               |                |               | 0.516   |
| Mean                                  | 85.5           | 86.6          |         |
| Median                                | 90             | 90            |         |
| Range                                 | 70-100         | 70-100        |         |
| T-Stage – no. (%)                     |                |               | 0.331   |
| T1                                    | 0 (0)          | 0 (0)         |         |
| T2                                    | 13 (26.5)      | 8 (18.2)      |         |
| T3                                    | 26 (53.1)      | 30 (68.2)     |         |
| T4                                    | 10 (20.4)      | 6 (13.2)      |         |
| N-Stage – no. (%)                     |                |               | 0.507   |
| N0                                    | 10 (20.4)      | 11 (25)       |         |
| N1                                    | 28 (57.1)      | 26 (59.1)     |         |
| N2                                    | 11 (22.4)      | 6 (13.6)      |         |
| N3                                    | 0 (0)          | 1 (2.3)       |         |
| Grade – no. (%)                       |                |               | 0.367   |
| G1                                    | 1 (2)          | 2 (4.5)       |         |
| G2                                    | 20 (40.8)      | 23 (52.3)     |         |
| G3                                    | 28 (57.1)      | 19 (43.2)     |         |
| Pretreatment Hemoglobin – g/dl        |                |               | 0.394   |
| Mean                                  | 12.8           | 13.1          |         |
| Median                                | 12.6           | 13.5          |         |
| Range                                 | 9.5-15.9       | 5.2-17.1      |         |
| Location (Distance from dental arcade to cranial tumor border) – cm | | | 0.031 |
| Mean                                  | 26.4           | 23.7          |         |
| Median                                | 27             | 22            |         |
| Range                                 | 15-37          | 10-38         |         |
| Histology – no. (%)                   |                |               | 0.491   |
| Squamous cell                         | 41 (83.7)      | 39 (88.6)     |         |
| Adeno                                 | 8 (16.3)       | 5 (11.4)      |         |
| Cumulative RT dose – Gy               |                |               | 0.010   |
| Mean                                  | 55.4           | 57.2          |         |
| Median                                | 54             | 56.8          |         |
| Range                                 | 50.4-70.2      | 50–61.2       |         |

Figure 1 illustrates results of local relapse rate (LR), OS and PFS for both groups. The 1- and 3-year LR was 20.4% and 28.6% in the 3DCRT group and 15.9% and
22.7% in the IMRT group, respectively \((p = 0.620)\). Median PFS in the respective groups were 13.8 and 16.6 months, which corresponded to 3- and 5-year PFS of 32.4% and 21% compared to 37.4% and 31.6%, respectively \((p = 0.448)\). Median OS in the respective cohorts were 18.4 and 42.0 months, which corresponded to 3- and 5-year OS of 35.5% and 23.9% compared to 50.9% and 38.9%, respectively \((p = 0.198)\).

Univariate analysis (UVA) determined factors associated with LR, PFS, and OS (Table 2). None of the investigated factors influenced OS or PFS with statistically significant impact. However, there was a trend for worse OS and PFS for high-grade disease \((p = 0.052\) and \(p = 0.089\), respectively) and for improved PFS with higher pre-treatment hemoglobin levels \((p = 0.057)\). Higher cumulative RT doses beneficially impacted LR on UVA \((p = 0.004)\). Multivariate analysis (MVA) included the factors RT technique, KPS, T-stage, N-stage, Grading, tumor histopathology and RT dose. Besides the confirmation of a beneficial impact of increased RT doses on LR \((HR \ 0.686, 95\%-CI \ 0.524 \ – \ 0.897; p = 0.006)\) and a borderline significant worse OS for high-grade tumors \((HR \ 1.743, 95\%-CI \ 1.003 \ – \ 3.029; p = 0.049)\) MVA did not reveal any further significant findings.

Acute, radiation-related toxicities experienced by both cohorts are displayed in Table 3. These predominantly included dysphagia, radiodermatitis and nausea/vomiting. Of note, dysphagia was observed in 70.5% for patients in the IMRT group vs. 42.9% in the 3DCRT group \((p = 0.067)\). Owing to a short follow-up period and assumed issues with data integrity regarding late toxicity reporting in the cohorts, late toxicities were unable to be reliably presented herein.

In terms of dosimetric analysis, detailed treatment plan information was available in 76 patients. Basic dosimetric parameters of 3DCRT and IMRT plans are shown in Table 4. A trend towards larger PTVs was observed for IMRT \((p = 0.060)\). There were no significant differences in normal tissue exposure between treatment techniques.

**Discussion**

In our study cohort, the choice of radiation technique (3DCRT or IMRT) did not significantly influence survival in definitive chemoradiotherapy for esophageal cancer patients. These results correspond to previous findings \([9, 10]\), yet contradictory results have been presented as well \([13]\). Nevertheless, the value of such an analysis is not diminished, because there is still a lack of data regarding the potential value of IMRT in the definitive, relatively dose-escalated setting. This will undoubtedly be an important issue in the coming years as the use of IMRT for EC increases \([23]\).

The novelty and emphasis of our data were aimed at detecting differences in outcome endpoints in the setting of relative dose-escalation (in the definitive setting). Although median OS was 42.0 months with IMRT compared to 18.4 months with 3DCRT, this difference did not reach statistical significance. However, LR was significantly increased by higher cumulative radiation doses. Interestingly, radiation modality did not show a noticeable impact on LR though confounder analysis revealed a significantly higher mean cumulative RT dose in the IMRT group. We suppose that this difference between both groups, namely 1.8 Gy (3DCRT 55.4 Gy vs. IMRT 57.2 Gy, \(p = 0.01)\), is too small to translate into a considerable outcome difference of radiation techniques. However, our data reveal a dose-relationship resulting in an increased local tumor control with higher radiation doses. This finding is in line with other investigations that have noted outcome enhancements for dose...

**Table 2** Hazard ratios (HR) with 95%-confidence intervals (CI) in univariate analysis for OS, PFS and LR

| Parameter            | OS HR [95% CI] | p-value | PFS HR [95% CI] | p-value | LR HR [95% CI] | p-value |
|----------------------|----------------|---------|----------------|---------|----------------|---------|
| RT mode (IMRT vs. 3DCRT) | 0.716 [0.430; 1.191] | 0.198 | 0.830 [0.512; 1.344] | 0.448 | 0.812 [0.356; 1.852] | 0.620 |
| Age (continuous)     | 1.006 [0.978; 1.035] | 0.676 | 1.009 [0.981; 1.037] | 0.525 | 0.962 [0.906; 1.022] | 0.211 |
| KPS (continuous)     | 1.004 [0.973; 1.035] | 0.816 | 1.024 [0.992; 1.057] | 0.138 | 0.988 [0.940; 1.039] | 0.644 |
| T-stage (T3/4 vs. T1/2) | 1.177 [0.637; 2.178] | 0.603 | 1.226 [0.679; 2.212] | 0.499 | 1.170 [0.411; 3.328] | 0.768 |
| N-stage (N1-3 vs. N0) | 1.493 [0.779; 2.863] | 0.228 | 1.399 [0.764; 2.561] | 0.277 | 1.218 [0.408; 3.635] | 0.723 |
| Grade (G3 vs. G1/2)  | 1.651 [0.996; 2.737] | 0.052 | 1.518 [0.938; 2.456] | 0.089 | 1.040 [0.453; 2.374] | 0.926 |
| Pretreatment Hemoglobin | 0.930 [0.821; 1.054] | 0.255 | 0.886 [0.783; 1.003] | 0.057 | 0.975 [0.821; 1.157] | 0.768 |
| Location             | 1.002 [0.960; 1.046] | 0.935 | 0.992 [0.952; 1.033] | 0.689 | 1.030 [0.958; 1.107] | 0.422 |
| Histology (Adeno vs. SCC) | 1.555 [0.786; 3.076] | 0.205 | 1.630 [0.851; 3.125] | 0.141 | 1.354 [0.489; 3.750] | 0.560 |
| RT dose (continuous) | 0.946 [0.881; 1.015] | 0.122 | 0.955 [0.893; 1.021] | 0.173 | 0.763 [0.635; 0.916] | 0.004 |
| Treatment year (continuous) | 1.021 [0.934; 1.116] | 0.646 | 1.043 [0.958; 1.135] | 0.329 | 1.041 [0.893; 1.213] | 0.606 |
escalation [24]. In contrast, the RTOG 9405 trial did not discern advantages from dose-escalation [25], albeit with now-outdated techniques. In summary, our data support the hypothesis that increased radiation doses improve patient outcomes; however, the potential benefit of dose-escalation in EC remains inconclusive due to the heterogeneity of evidence [26].

Nevertheless, there is little debate that IMRT theoretically allows for safer dose-escalation. Dosimetric investigations have determined that advanced IMRT techniques provide numerical advantages over 3DCRT, but without outcome differences [27, 28]. This particularly applies to a reduction of high dose exposure to the OAR. For example, Münch et al. have demonstrated a significant reduction of the lung V30Gy with VMAT (6.6%) compared to 3DCRT (11%) and of the heart V30Gy (17.7% with VMAT vs. 50.4% with 3DCRT) [27]. In contrast, our study failed to demonstrate any significant differences in OAR dose exposure. However, slightly lower doses to the spinal cord and the heart were observed for IMRT and MLD was equal despite a larger PTV volume by trend of IMRT patients. Of note, the nature of IMRT and arc therapy results in increased low-dose areas to the heart and lungs, the ramifications of which are also unclear presently. In the study of

### Table 3

| Toxicity                  | 3DCRT (n = 49) | IMRT (n = 44) | p-value |
|---------------------------|----------------|---------------|---------|
| Dysphagia – no. (%)       |                |               | 0.067   |
| absolute                  | 21 (42.9)      | 31 (70.5)     |         |
| G1                        | 4 (8.2)        | 9 (20.5)      |         |
| G2                        | 15 (30.6)      | 15 (34.1)     |         |
| G3                        | 2 (4.1)        | 6 (13.6)      |         |
| G4                        | 0              | 1 (2.3)       |         |
| Radiodermatitis – no. (%) |                |               | 0.638   |
| absolute                  | 14 (28.6)      | 17 (38.6)     |         |
| G1                        | 9 (18.3)       | 13 (29.6)     |         |
| G2                        | 3 (6.1)        | 2 (4.6)       |         |
| G3                        | 2 (4.1)        | 2 (4.6)       |         |
| G4                        | 0              | 0             |         |
| Nausea/Vomiting – no. (%) |                |               | 0.602   |
| absolute                  | 11 (22.4)      | 9 (20.5)      |         |
| G1                        | 8 (16.3)       | 4 (9.1)       |         |
| G2                        | 2 (4.1)        | 4 (9.1)       |         |
| G3                        | 1 (2.0)        | 1 (2.3)       |         |
| G4                        | 0              | 0             |         |
| Mucositis – no. (%)       |                |               | 0.518   |
| absolute                  | 7 (14.3)       | 7 (15.9)      |         |
| G1                        | 2 (4.1)        | 0             |         |
| G2                        | 4 (8.2)        | 4 (9.1)       |         |
| G3                        | 1 (2.0)        | 3 (6.8)       |         |
| G4                        | 0              | 0             |         |
| Bleeding – no. (%)        |                |               | 0.341   |
| absolute                  | 1 (2.0)        | 0             |         |
| G1                        | 1 (2.0)        | 0             |         |
| G2                        | 0              | 0             |         |
| G3                        | 0              | 0             |         |
| G4                        | 0              | 0             |         |
| Pneumonitis – no. (%)     |                |               | 0.557   |
| absolute                  | 3 (6.1)        | 1 (2.3)       |         |
| G1                        | 1 (2.0)        | 0             |         |
| G2                        | 2 (4.1)        | 1 (2.3)       |         |
| G3                        | 0              | 0             |         |
| G4                        | 0              | 0             |         |

### Table 4

| Dosimetric parameter       | 3DCRT (n = 39) | IMRT (n = 37) | p-value |
|-----------------------------|----------------|---------------|---------|
| Boost concept – no. (%)     |                |               | <0.001  |
| sequential                  | 36 (92.3)      | 16 (43.2)     |         |
| integrated                  | 0 (0)          | 16 (43.2)     |         |
| none                        | 3 (7.7)        | 5 (13.5)      |         |
| PTV volume - ml             |                |               | 0.060   |
| Mean                        | 667            | 796           |         |
| Median                      | 657            | 755           |         |
| Range                       | 229-1236       | 193-1715      |         |
| Boost PTV volume - ml       |                |               | 0.139   |
| Mean                        | 236            | 192           |         |
| Median                      | 230            | 175           |         |
| Range                       | 73-528         | 24-624        |         |
| Mean lung dose - Gy         |                |               | 0.651   |
| Mean                        | 12.6           | 12.2          |         |
| Median                      | 12.3           | 12.4          |         |
| Range                       | 4.8-20.2       | 3.1-18.9      |         |
| Mean heart dose - Gy        |                |               | 0.158   |
| Mean                        | 18.1           | 14.2          |         |
| Median                      | 19.7           | 14.5          |         |
| Range                       | 0.4-38.8       | 0.2-37.5      |         |
| Spinal cord Dmax - Gy       |                |               | 0.229   |
| Mean                        | 36.8           | 35.1          |         |
| Median                      | 38             | 36.3          |         |
| Range                       | 14.2-45.9      | 8-43.2        |         |
Münch et al., the V50Gy of the lungs and the heart were 90.1% and 100% with VMAT compared to 79.7% and 91% with 3DCRT, respectively [27]. Using rotational techniques, low-dose areas to the lung have been higher in some studies than the recommended limits in other (lung cancer) studies [13, 29]. It cannot go unmentioned, however, that inverse-planned therapies (e.g. IMRT, arc therapy, etc.) are heavily dependent on nuances of treatment planning, technique, delivery, and optimization, which can lead to a variety of potential results [30]. The use of helical IMRT herein has heretofore never been reported as a modality of IMRT delivery, and could be of further interest for future investigations.

Though there is a knowledge gap regarding the role of IMRT in EC, compelling data suggest that IMRT and other advanced techniques may decrease postoperative complications when used in the setting of nCRT, thus potentially decreasing surgical morbidity and mortality [17]. Notably, Lin et al. analyzed multiple cancer registries and performed inverse probability of treatment weighting-adjusted multivariate analysis [31]. Therein, radiation modality (3DCRT vs. IMRT) was independently associated with all-cause, other, and cardiac-specific mortality. It is thus important to be cognizant of cardiac doses in a neoplasm for which the heart was historically not a major priority but long-term survival is now increasing; this is similar to the findings of the RTOG 0617 trial in locally advanced non-small cell lung cancer (NSCLC) [32]. Because IMRT affords lower cardiac doses for both tumors, it has been postulated that IMRT should be the standard for NSCLC, despite a similar lack of comparative data in both NSCLC and EC [33].

There are several limitations of our study. In addition to the retrospective nature and smaller sample size, it is recognized that groups were somewhat imbalanced in terms of tumor location. The rather short follow-up time may also likely underestimate cardiac events, as these typically take at least 5–10 years to develop. Although the year of treatment was not a significant factor on outcome in UVA, advancements in diagnostics and treatment options after the first line during the inclusion period of twelve years may cause an undiscovered bias. Other newer supportive technologies also cannot be overlooked, such as staging PET and 4-dimensional CT planning. Moreover, patients with poor KPS were excluded, which also contribute a nontrivial proportion of EC patients. Also, limiting applicability were the low numbers of adenocarcinoma, as well as institutional/regional biases in referring patients for surgery versus definitive therapy. Taken together, however, our data should ideally signal other reports as to whether IMRT is indeed appropriate for several patient subgroups over 3DCRT.

If clinical benefits of IMRT in the definitive and/or neoadjuvant treatment of EC are eventually proven, it could signal further testing of an even more new modality known as proton beam therapy. Though issues with economic costs remain, this modality has been also associated with low perioperative complications, which could potentially offset these costs [34–36]. A randomized trial of photons versus protons for EC is currently underway (NCT01512589).

Conclusions
These data showed that when comparing 3DCRT and IMRT, survival of patients with esophageal cancer is not affected. However, we found a lower rate of local relapses in the IMRT group potentially owing to dose-escalation. Further validation is needed from prospective studies.

Abbreviations
3DCRT: 3D conformal radiotherapy; CI: Confidence interval; CRT (dCRT/ nCRT): Chemoradiotherapy (definitive/neoadjuvant); CTV: Clinical target volume; Dmax: Maximum dose; EC: Esophageal cancer; HR: Hazard ratio; IMRT: Intensity-modulated radiotherapy; LR: Local relapse; MLD: Mean lung dose; MVA: Multivariate analysis; NSCLC: Non-small cell lung cancer; OAR: Organ(s) at risk; OS: Overall survival; PET: Positron emission tomography; PFS: Progression-free survival; PTV: Planning target volume; RTOG: Radiation Therapy Oncology Group; UVA: Univariate analysis; VMAT: Volumetric Arc Therapy

Acknowledgements
Not applicable.

Funding
Funding to pay the Open Access publication charges for this article was provided by Deutsche Forschungsgemeinschaft (DFG) and Ruprecht-Karls-Universität Heidelberg within the funding programme Open Access Publishing.

Availability of data and materials
The data that support the findings of this study are available from the corresponding author on reasonable request.

Authors’ contributions
MFH, KL, JD and FS designed and planned the study. MFH and KL carried out data collection. MFH and LU performed statistical analysis. MFH, SAK, VV, JD and FS were responsible for clinical interpretation of data. MFH and VV drafted the manuscript and all authors revised it critically. All authors read and approved the final manuscript.

Ethics approval and consent to participate
All studies on patient data were carried out with approval of the institutional ethical review committee and in accordance with national law and the Helsinki Declaration of 1975 (in its current, revised form).

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details
1. Department of Radiation Oncology, University Hospital of Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany. 2. National Center for Radiation Research in Oncology (NCCR), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Received: 15 March 2017 Accepted: 4 August 2017
Published online: 15 August 2017

References

1. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology - Esophageal and Esophagogastric Junction Cancers (v 2.2016, accessed September 20th 2016).
2. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. N Engl J Med. 2012;366:2074–84.
3. Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation With and Without Surgery in Patients With Locally Advanced Squamous Cell Carcinoma of the Esophagus. J Clin Oncol. 2005;23:2310–7.
4. Bedené L, Michel P, Bouché O, et al. Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cell Carcinoma of the Esophagus: FFCD 9102. J Clin Oncol. 2011;29:1160–8.
5. Kranefelder M, Schuster T, Geinitz H, et al. Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell carcinoma. Br J Surg. 2011;98:768–83.
6. Lloyd S, Chang BW. Current strategies in chemoradiation for esophageal cancer. J Gastroint Oncol. 2014;5:156–65.
7. Conroy T, Galais M-P, Raoul J-L, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE-ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15:305–14.
8. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–9.
9. Freilich J, Hoffe SE, Almhanna K, et al. Comparative outcomes for three-dimensional conformal versus intensity-modulated radiation therapy for esophageal cancer. Dis Esophagus. 2015;28:352–7.
10. Tan L, Xiao Z, Zhang H, et al. Results and prognostic factors of 3-dimensional conformal radiotherapy and intensity-modulated radiotherapy for esophageal carcinoma. Neoplasma. 2015;62:777–86.
11. Roedel F, Nicolay NH, Nguyen T, et al. Intensity modulated radiotherapy (IMRT) with concurrent chemoradiotherapy as definitive treatment of locally advanced esophageal cancer. Radiat Oncol. 2014;9:191.
12. Cao C, Luo J, Gao L, et al. Intensity-modulated radiotherapy for cervical esophageal squamous cell carcinoma: clinical outcomes and patterns of failure. Eur Arch Otorhinolaryngol. 2015;273:741–7.
13. Lin SH, Wang L, Myles B, et al. Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys. 2012;84:1078–85.
14. Wang S, Liao Z, Vaporciyan AA, et al. Investigation of clinical and dosimetric factors associated with postoperative pulmonary complications in esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2006;64:692–9.
15. Kumar G, Ravat S, Puri A, et al. Analysis of dose-volume parameters predicting radiation pneumonitis in patients with esophageal cancer treated with 3D-conformal radiotherapy or IMRT. Jpn J Radiol. 2011;30:18–24.
16. Nomura M, Kodaia T, Furutani K, et al. Predictive factors for radiation pneumonitis in oesophageal cancer patients treated with chemoradiotherapy without prophylactic nodal irradiation. Br J Radiol. 2012;85:B13–8.
17. Wang J, Wei C, Tucker SL, et al. Predictors of Postoperative Complications After Tramodality Therapy for Esophageal Cancer. Int J Radiat Oncol Biol Phys. 2013;83:885–91.
18. Zhao Y, Chen L, Zhang S, et al. Predictive factors for acute radiation pneumonitis in postoperative intensity modulated radiation therapy and volumetric modulated arc therapy of esophageal cancer. Thorac Cancer. 2015;6:49–57.
19. Hayashi K, Fujisawa Y, Nomura M, et al. Predictive factors for periocardial effusion identified by heart dose–volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy. Br J Radiol. 2014;87:20140168.
20. Beukema JC, van Luijk P, Widder J, et al. Is cardiac toxicity a relevant issue in the radiation treatment of esophageal cancer? Radiother Oncol. 2015;114:85–90.
21. Ogino I, Watanabe S, Ishibashi N, et al. Symptomatic radiation-induced cardiac disease in long-term survivors of esophageal cancer. Strahlenther Onkol. 2016;192(6):359–67.
22. Ghazali L, Verma V, Denniston KA, et al. Radiation Therapy and Cardiac Death in Long-Term Survivors of Esophageal Cancer: An Analysis of the Surveillance, Epidemiology, and End Result Database. PLoS One. 2016;11:e0158916.
23. Verma V, Moreno AC, Lin SH. Advances in Radiotherapy Management of Esophageal Cancer. J Clin Med. 2016;5:91.
24. Chen CY, Li CC, Chien CR. Does higher radiation dose lead to better outcome for non-operated localized esophageal squamous cell carcinoma patients who received concurrent chemoradiotherapy? A population based propensity-score matched analysis. Radiother Oncol. 2016;120:136–9.
25. Minsky BD, Pajak TF, Ginsberg RJ, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation Therapy. J Clin Oncol. 2002;20:1167–74.
26. Brower JV, Chen S, Basetti MF, et al. Radiation Dose Escalation in Esophageal Cancer Revisted: A Contemporary Analysis of the National Cancer Data Base, 2004 to 2012. Int J Radiat Oncol Biol Phys. 2016;96:895–83.
27. München S, Aichmeier S, Hapfelmeier A, et al. Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3D conformal radiotherapy or VMAT. Strahlenther Onkol. 2016;192(10):722–9.
28. Fakhri K, Oechsner M, Kampfer S, et al. Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk. Strahlenther Onkol. 2013;189:293–300.
29. Zhang WZ, Zhao TT, Lu JY, et al. Volumetric Modulated Arc Therapy vs. c-IMRT for the Treatment of Upper Thoracic Esophageal Cancer. PLoS One. 2015;10:e0121385.
30. Wang S, Liao Z, Wei X, et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys. 2006;66:1399–407.
31. Lin SH, Zhang N, Godby J, et al. Radiation modality use and cardiopulmonary mortality risk in elderly patients with esophageal cancer. Cancer. 2016;122:917–28.
32. Bradley JD, Paulus R, Komaki R, et al. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIA or IIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol. 2015;16:187–99.
33. Chang JY. Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer. Semin Radiat Oncol. 2015;25:110–6.
34. Chung MD, Hallemeyer CL, Jabbour SK, et al. Improving Outcomes for Esophageal Cancer using Proton Beam Therapy. Int J Radiat Oncol Biol Phys. 2016;95:488–97.
35. Verma V, Lin SH, Simone CB II, et al. Clinical outcomes and toxicities of proton radiotherapy for gastrointestinal neoplasms: a systematic review. J Gastroint Oncol. 2016;7:644–64.
36. Verma V, Mishra MV, Mehta MP. A systematic review of the cost and cost-effectiveness studies of proton radiotherapy. Cancer. 2016;122:1483–501.